Related Experiment Video
Updated: Jun 2, 2026

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
Published on: October 14, 2016
Two pediatric osteosarcoma cases with delayed methotrexate excretion: its clinical course and management
Kang Min Lee1, Hee Woo Lee, Seung Yeon Kim
1Department of Pediatrics, Korea Cancer Center Hospital, Seoul, Korea.
Abstract:
High-dose methotrexate (MTX) chemotherapy extends the duration of hospitalization and introduces the risks of serious complications related to delayed MTX excretion. The treatment of delayed MTX excretion is largely dependent on invasive measures such as hemodialysis because the clinical data regarding the efficacy or safety of carboxypetidase G(2) is limited. We report here on the cases of two pediatric osteosarcoma patients with delayed MTX excretion and who were successfully managed using supportive measures. Potential life-threatening complications were prevented by administering high doses of leucovorin.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Therapeutic Drug Monitoring: Affecting Factors
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Distribution
Treatment Resistent Cancers

